ClinicalTrials.gg
CompletedNCT02675803Updated Dec 11, 2020

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients

A Phase 1 interventional study of VAY736 and VAY736 placebo in Rheumatoid Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-12-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 6 months after the study started (first participant enrolled Dec 2010, registered Jul 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies in Arthritis, Rheumatoid by Novartis — 1 open to participants now, 4 under way, none of them phase 3. Arthritis, Rheumatoid · Novartis.

Enrollment
21st of 30
65 · median 98
Started
2010
the only one that year
Phase 1
7 of 30
1 open now
Registered
22nd of 30
by date

Among the 30 studies in Arthritis, Rheumatoid by Novartis, this one is the 21st largest by enrollment, is the only one that started in 2010, is one of 7 in phase 1, and was the 22nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 30 studies in Arthritis, Rheumatoid by Novartis is open now. Recruiting first, the newest first:

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Arthritis, Rheumatoid by Novartis, or all of them as a file.
02

Study summary

This study investigated the safety and tolerability of VAY736 administered as single ascending doses of intravenous infusion, subcutaneous injection and repeated subcutaneous injections in rheumatoid arthritis patients.

Read the detailed description

This study had three sequential parts which investigated the safety and tolerability of VAY736 administered as single ascending doses of intravenous infusion (Part 1), single ascending doses of subcutaneous injection (Part 2), and repeated subcutaneous injections of fixed doses (Part 3), respectively, in rheumatoid arthritis patients. Part 1 was double blind, placebo controlled, with 11 cohorts. Part 2 was open-label study with 2 dosing cohorts. Part 3 was open-label study with 1 fixed-dose cohort.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid arthritis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active disease despite methotrexate treatment 5 to 20 mg/week for Parts 1 and 2; methotrexate treatment 5 to 20 mg/week for Part 3
  • Fulfilled 2010 American College of Rheumatolody (ACR)/European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis for Part 1 and Part 2. For Part 3, fulfilled 2010 American College of Rheumatolody (ACR)/)/European League Against Rheumatism (EULAR) classification criteria or/and 1987 American College of Rheumatolody (ACR) classification criteria for rheumatoid arthritis;
  • Methotrexate ≥ 16 weeks, stable dose ≥ 8 weeks

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with a B cell-depleting biologic agent.
  • disease other than RA except concurrent Sjogren's syndrome
  • Adult juvenile rheumatoid arthritis
  • ARA functional class IV disease of ACR Revised Steinbrocker Classification
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    VAY736

    VAY736 active

    Biological: VAY736

  • Placebo comparator
    Placebo

    VAY736 placebo

    Biological: VAY736 placebo

Interventions

  • BiologicalVAY736

    VAY736 treatment

  • BiologicalVAY736 placebo

    VAY736 placebo

06

What researchers measure

Primary outcomes

  1. Safety and tolerability as measured by the number of patients wth adverse events

    Part 1 The number of patients with adverse events after single intravenous (i.v.) dose of VAY736. Patients are assessed weekly up to 34 weeks post dose or until B cells reach the recovery criteria Part 2 The number of patients with adverse events after single subcutaneous (s.c.) dose of VAY736. Patients are assessed weekly, bi-weekly, then every 4, 8 and 12 weeks up to 188 weeks post dose or until B cells reach the recovery criteria. Part 3 The number of patients with adverse events after repeated subcutaneous (s.c) injections of a fixed dose of VAY736. Patients are assessed bi-weekly, then every 4 weeks and 8 weeks up to 27 weeks from the first dose.

    Time frame: 27-188 weeks

  2. Absolute bioavailability of VAY736: The ratio of area under curve (AUC) for s.c dose and for intravenous dose

    Part 2 The ratio of area under curve (AUC) for single s.c dose and intravenous dose is determined

    Time frame: 188 weeks

  3. Plasma pharmacokinetics of VAY736: The area under the plasma concentration-time curve from time zero to the end of the dosing interval (AUCtau)

    In Part 3: After the first and last s.c. doses, the area under the plasma concentration-time curve from time zero to the end of the dosing interval (AUCtau) will be determined

    Time frame: 27 weeks

  4. Plasma pharmacokinetics of VAY736: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)

    In Part 3: After the first and last s.c. doses, the Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) will be determined.

    Time frame: 27 weeks

  5. Plasma pharmacokinetics of VAY736: Observed maximum plasma concentration following drug administration (Cmax)

    In Part 3: After the first and last s.c. doses, the Observed maximum plasma concentration following drug administration (Cmax) will be determined

    Time frame: 27 weeks

  6. Plasma pharmacokinetics of VAY736: Time to reach the maximum concentration after drug administration (Tmax)

    In Part 3: After the first and last s.c. doses, the time to reach the maximum concentration after drug administration (Tmax) will be determined

    Time frame: 27 weeks

  7. Plasma pharmacokinetics of VAY736: The terminal elimination half-life (T1/2)

    In Part 3: After the first and last s.c. doses, the terminal elimination half-life (T1/2) will be determined

    Time frame: 27 weeks

  8. Plasma pharmacokinetics of VAY736: Area under the plasma concentration-time curve from time zero to infinity (AUCinf)

    In Part 3: After the first and last s.c. doses, Area under the plasma concentration-time curve from time zero to infinity (AUCinf) will be determined.

    Time frame: 27 weeks

  9. Plasma pharmacokinetics of VAY736: concentration of VAY736 during the treatment period, before each dose (Ctrough)

    In Part 3: After the first and last s.c. doses, the concentration of VAY736 during the treatment period, before each dose (Ctrough) will be determined

    Time frame: 27 weeks

  10. Safety and tolerability as measured by the percentage of patients wth adverse events

    Part 1 The percentage of patients with adverse events after single intravenous (i.v.) dose of VAY736. Patients are assessed weekly up to 34 weeks post dose or until B cells reach recovery criteria. Part 2 The percentage of patients with adverse events after single subcutaneous (s.c.) dose of VAY736. Patients are assessed weekly, bi-weekly, then every 4, 8 and 12 weeks up to 68 weeks post dose or until B cells reach recovery criteria.. Part 3 The percentage of patients with adverse events after repeated subcutaneous (s.c) injections of a fixed dose of VAY736. Patients are assessed bi-weekly, then every 4 weeks and 8 weeks up to 27 weeks from the first dose.

    Time frame: 27-188 weeks

Secondary outcomes

  1. pharmacodynamics of VAY736

    B cell depletion/recovery after single i.v. dose of VAY736, single s.c. dose of VAY736 and multiple fixed s.c. doses of VAY736 administration in the 3 parts of the study

    Time frame: 27-188 weeks

  2. Immunogenicity of VAY736

    Immunogenicity after administration of single i.v. dose of VAY736, single s.c. dose of VAY736 and multiple fixed s.c. doses of VAY736 in 3 parts of the study.

    Time frame: 27-188 weeks

  3. Plasma bioavailability of VAY736: The ratio of area under curve (AUC) for repeated s.c doses and for intravenous dose

    Part 3 The ratio of area under curve (AUC) for repeated s.c doses and for intravenous dose is determined

    Time frame: 27 weeks

  4. Plasma pharmacokinetics of VAY736: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)

    The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) will be determined after single i.v. dose and s.c. dose of VAY736 in Part 1 and Part 2 respectively

    Time frame: 34-188 weeks

  5. Plasma pharmacokinetics of VAY736: Area under the plasma concentration-time curve from time zero to infinity (AUCinf)

    The area under the plasma concentration-time curve from time zero to infinity (AUCinf) will be determined after single i.v. dose and s.c. dose of VAY736 in Part 1 and Part 2 respectively.

    Time frame: 34-188 weeks

  6. Plasma pharmacokinetics of VAY736: Observed maximum plasma concentration following drug Administration (Cmax)

    The Observed maximum plasma concentration following drug administration (Cmax) will be determined after single i.v. dose and s.c. dose of VAY736 in Part 1 and Part 2 respectively

    Time frame: 34-188 weeks

  7. Plasma pharmacokinetics of VAY736: Time to reach the maximum concentration after drug administration (Tmax)

    The time to reach the maximum concentration after drug administration (Tmax) will be determined after single i.v. dose and s.c. dose of VAY736 in Part 1 and Part 2 respectively

    Time frame: 34-188 weeks

07

Study locations

1 site
  • Novartis Investigative Site
    Berlin, 10117, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2010 to primary completion in Jan 2018, 85 months.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 85 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2015
First posted
Feb 5, 2016
StartActual
Dec 20, 2010
Primary completionActual
Jan 22, 2018
CompletionActual
Jan 22, 2018
Last update
Dec 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02675803
Responsible party
Sponsor
First posted
Feb 5, 2016
Start date
Dec 20, 2010
Primary completion
Jan 22, 2018
Completion
Jan 22, 2018
Last update
Dec 11, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion